scholarly journals Recombinant activated factor VII treatment of severe bleeding in cardiac surgery patients: a retrospective analysis of dosing, and efficacy and safety outcomes

Critical Care ◽  
2007 ◽  
Vol 11 (Suppl 2) ◽  
pp. P381
Author(s):  
M Liebl ◽  
F Masud ◽  
F Bostan ◽  
E Chi ◽  
S Pass ◽  
...  
Keyword(s):  
Cardiac Surgery ◽  
Retrospective Analysis ◽  
Factor Vii ◽  
Severe Bleeding ◽  
Efficacy And Safety ◽  
Recombinant Activated Factor Vii ◽  
Activated Factor Vii ◽  
Safety Outcomes

Recombinant activated factor VII for refractory bleeding after cardiac surgery—A retrospective analysis of safety and efficacy

2005 ◽  
Vol 33 (10) ◽  
pp. 2241-2246 ◽  
Author(s):  
Christian von Heymann ◽  
Uwe Redlich ◽  
Uday Jain ◽  
Marc Kastrup ◽  
Torsten Schroeder ◽  
...  
Keyword(s):  
Cardiac Surgery ◽  
Retrospective Analysis ◽  
Factor Vii ◽  
Recombinant Activated Factor Vii ◽  
Safety And Efficacy ◽  
Activated Factor Vii

Bleeding after cardiac surgery

2006 ◽  
Vol 26 (S 02) ◽  
pp. S76-S86
Author(s):  
C. Spies ◽  
H. Grubitzsch ◽  
H. Schönfeld ◽  
M. Sander ◽  
Th. Volk ◽  
...  
Keyword(s):  
Cardiac Surgery ◽  
Blood Loss ◽  
Factor Vii ◽  
Coagulation System ◽  
Severe Bleeding ◽  
International Studies ◽  
Recombinant Activated Factor Vii ◽  
Activated Factor Vii ◽  
Increased Risk ◽  
Heart Lung Machine

SummaryCardiac surgery carries the risk of significant blood loss requiring the transfusion of blood products. In addition to such blood loss, international studies have shown that severe bleeding necessitating re-operation occurs in 3–5% of patients. Morbidity and mortality are significantly increased, so effective and safe haemostatic measures will decisively improve outcome of patients.Recombinant activated factor VII (rFVIIa) has been approved for the treatment of patients with inhibitor haemophilia, as well as with Glanzmann’s thrombasthenia and factor VII deficiency. Many publications have appeared in the last few years which report the successful and reliable use of rFVIIa for the treatment of refractory bleeding after cardiac surgery. This review presents the pathophysiological changes in the coagulation system which occur when a heart-lung machine is used and which have been blamed for an increased risk of bleeding in patients who have undergone cardiac surgery. Published experience with rFVIIa in paediatric and adult cardiac surgery is presented and discussed critically with regard to the efficacy and safety of its use.

The Utility of Thromboelastography for Guiding Recombinant Activated Factor VII Therapy for Refractory Hemorrhage After Cardiac Surgery

2009 ◽  
Vol 23 (6) ◽  
pp. 828-834 ◽  
Author(s):  
Marcin Wąsowicz ◽  
Massimiliano Meineri ◽  
Stuart M. McCluskey ◽  
Nicholas Mitsakakis ◽  
Keyvan Karkouti
Keyword(s):  
Cardiac Surgery ◽  
Factor Vii ◽  
Recombinant Activated Factor Vii ◽  
Activated Factor Vii
Sign in / Sign up

Export Citation Format

Share Document